Sterling Biotech Limited reported unaudited standalone earnings results for the first quarter ended June 30, 2016. For the quarter, the company's net sales/income from operations was INR 1,030.034 million compared to INR 1,250.784 million a year ago. Loss from operations before other income, finance costs was INR 543.008 million compared to INR 482.632 million a year ago. Loss from ordinary activities after finance costs but before tax was INR 1,338.688 million compared to INR 1,304.336 million a year ago. Net loss was INR 875.388 million compared to INR 852.936 million a year ago. Diluted loss per share before and after extraordinary items was INR 2.02 compared to INR 1.97 a year ago.